vehicle

Phosphatidylcholines,soya (Soybean phosphatidylcholine) 是从大豆中提取的磷脂酰胆碱，可作为动物给药的载体，可用于脂质体的制备。

D-Lin-MC3-DMA 是一种递送 siRNA 载体，是一种可离子化的氨基脂质类化合物。

5A2-SC8 是一种可电离阳离子的脂质，是小 RNA 传递的理想载体，能够与带负电荷的细胞膜相互作用，可用于基因传递和药物输送。

HP-β-CD (HP-β-CD) 是一种药物递送载体，可提高稳定性和利用度。

Polyoxyl 10 oleyl ether is an emulsifying agent. It is used as vehicle for organic compunds in aqueous solutions.

Benz[a]anthracene是一种由四个稠合苯环组成的大型多环芳烃 (PAH)，主要作为有机物不完全燃烧的副产物形成。根据毒理学数据，Benz[a]anthracene是一种人类致癌物。Benz[a]anthracene主要存在于烟草及香烟烟雾、煤焦油、车辆尾气排放以及某些加工食品中，使其成为癌症病理学研究中备受关注的化合物。

PZ-285 is a potent anticancer agent with similar antitumor activity to the clinically active agent Dox. Pz 285 improves survival, inhibits primary tumor regrowth, and inhibits lung tumor metastasis compared to vehicle control animals.

ML 23 is a melatonin analogue in the treatment and management of Parkinson's disease. ML-23 is a potential clinical candidate for the treatment of PD, and the present study has been undertaken to determine the efficacy of ML-23 in the 1-methyl-4-phenyl, 1

Ensartinib(X-396)是一种有效和具有口服活性的ALK/MET双重抑制剂，恩沙替尼可用于治疗ALK阳性的非小细胞肺癌(NSCLC)。

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg/ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg/kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg/kg to 2.5 mg/kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

The truncated glucagon-like peptides GLP-1(7-37) is naturally occurring peptide product of the preproglucagon gene that are synthesized primarily in the intestine and acts as incretin that are released from the intestine into the bloodstream in response to food and stimulate insulin secretion. GLP-1(7-37) produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in Sprague-Dawley Rats at a dosing rang of 0.5, 5, or 50 pmol/min/kg. Further, infusion of GLP-1(7-37) for 60 mins produced a small transitory increase in plasma insulin concentration in fasted rats and fed rats and a slight transitory decrease in plasma glucose concentration. Moreover, GLP-1(7-37) (5 pmol/min/kg IV) infusion for 6 h in Sprague-Dawley rats produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle[1].

KD-3010 is a peroxisome proliferator-activated receptor delta agonist potentially for the treatment of diabetes and obesity. KD-3010 dramatically ameliorates liver injury induced by carbon tetrachloride (CCl(4)) injections. Deposition of extracellular matrix proteins was lower in the KD3010-treated group than in the vehicle- or GW501516-treated group. Interestingly, profibrogenic connective tissue growth factor was induced significantly by GW501516, but not by KD-3010, following CCl(4) treatment.

Cipamfylline is a xanthine, a theophylline analogue, and is a potent and selective inhibitor of phosphodiesterase type 4 (PDE-4). Cipamfylline was tested in patients with a diagnosis of atopic dermatitis and in two human models of acute and chronic irritant contact dermatitis. The outcome of the study revealed that cipamfylline was more effective than vehicle in treating atopic dermatitis, but less effective than a group II steroid, hydrocortisone-17-butyrate both in the treatment of atopic dermatitis and irritant contact dermatitis. The absorption of cipamfylline and the subsequent systemic exposure might be the reason why further clinical studies with higher doses of cipamfylline have not been published.

Linoleyl methane sulfonate 可作为选择性的脂质载体，用于药物递送系统。

BGTC 是一种非氨基酸阳离子脂质。BGTC 可用于核酸递送。

18:1 PEG-PE 是一种聚乙二醇/磷脂酰乙醇胺偶联物，可用于活性分子输送。

Penetratin-Arg 是一种抗菌剂 (antimicrobial)，用于活性分子输送载体。

INX-SM-6适用于靶向输送抗炎药物。它能在PBMCS细胞中抑制LPS引发的IL-1β产生。

Nab-Paclitaxel为一种Paclitaxel纳米颗粒与白蛋白结合的制剂，展现出较高的疗效及耐受性。通过利用白蛋白传递Paclitaxel，Abraxane形成优异的药代动力学特性。

A12-Iso5-2DC18，一种电离性阳离子脂质，有效作为mRNA脂质传递载体。

Anti-FOLR1/FRA Antibody 是一种针对叶酸受体 alpha (FOLR1/FRA/FRα) 的人源化单克隆抗体。FOLR1 是一种糖基磷脂酰肌醇 (GPI) 锚定的膜蛋白，负责介导细胞对叶酸的高亲和力摄取。研究发现，FOLR1 在卵巢癌、乳腺癌、肺癌等多种上皮性肿瘤中显著过表达，而在正常组织（除了肾脏近端小管）中表达受限，使其成为理想的肿瘤靶点。Anti-FOLR1/FRA Antibody 通过特异性结合肿瘤细胞表面的 FOLR1，不仅能阻断 Lyn 激酶介导的信号传导从而抑制细胞增殖，还能诱导强效的抗体依赖性细胞毒性 (ADCC) 和补体依赖性细胞毒性 (CDC) 来直接杀伤肿瘤细胞。此外，作为 ADC (抗体-药物偶联物) 的靶向部分，它也是将细胞毒性药物（如 DM4）递送至肿瘤细胞内部的重要载体。

Tividenofusp alfa (DNL-310) 是由 IDS 和 Denali 专有的酶转运载体 (ETV) 结合形成的融合蛋白。

Anti-MUC17 Antibody 是一种在 CHO 细胞中表达的人源化单克隆抗体，靶向跨膜粘蛋白 MUC17（也称为 MUC3G）。该产物特异性识别 MUC17 的胞外结构域。MUC17 在多种胃肠道肿瘤（尤其是胃癌和结直肠癌）中呈高表达。该抗体通过与细胞表面的 MUC17 结合，介导抗体依赖性细胞介导的细胞毒性作用 (ADCC)，并可作为载体将偶联的治疗载荷（如在 ADC 研究中）定向递送至肿瘤细胞内部。

mPEG-CHO (MW 350) 能形成三维多孔支架，并在携带活性物质时充当递送载体。其上的 -CHO 官能团与壳聚糖链的 -NH2 官能团发生相互作用，生成戊二醛型加合物，从而实现 mPEG 的功能化。此功能化与交联过程可左右递送系统的刚性，使交联的共轭系统具备缓释功能。